Entities

Nexcade builds AI agents for freight forwarders, automating quotation, rate sourcing, tendering, bookings and related commercial workflows. Its agents combine information from emails, supplier portals, spreadsheets and transport-management systems, prepare work for review and carry shipment context between tasks. Freight teams control decisions while the software handles repetitive coordination and data entry. The company is based in London.

Measures, predicts and engineers protein-protein interactions for drug discovery. Its AlphaSeq experimental platform measures large numbers of binding affinities, while AlphaBind machine-learning models predict binding from protein sequences. The company uses these tools for its own therapeutic programs and pharmaceutical partnerships.

GRAI develops AI tools for interactive music remixing and social audio experiences.

Deploys batteries and distributed energy infrastructure at commercial sites, reducing electricity costs and supplying backup power and capacity for the grid.

Empatica develops AI-enabled medical wearables, physiological sensing, connected-health software and digital biomarkers for remote monitoring, clinical trials and research. Its neurological applications span epilepsy, Parkinson’s and movement disorders, sleep and actigraphy. Current products combine EmbracePlus and EmbraceMini wearables with the Care software suite and research APIs; E4 and Embrace2 are discontinued hardware. The company is co-founded by CEO Matteo Lai and Chief Scientist Rosalind Picard. Its public directory names five operating leaders and seven external medical/scientific supporters. The September2026 summit separately identifies scientific adviser Larsson Omberg. External supporters are distinguished from employees and statutory directors. Dated historical board and regulatory affiliations are retained separately; Marisa Cruz’s2022 CMO role is former. The privately reported100-plus employee headcount does not provide an individually published staff roster. Genuine own portraits cover the current named directory, with existing shared photographs preserved and unavailable historical portraits left explicit. The business operates through US Empatica Inc. inCambridge,Massachusetts and Italian regulated manufacturer Empatica Srl inMilan, VAT IT07462810966. Primary SEC CIK1606818 identifies the original US legal name Physiio International,Inc., formed2013, and the same issuer’s later EmpaticaInc. name. The2013 founding year refers to that US legal entity, without inventing dates for earlier research projects or unrelated namesakes. EpiMonitor’s FDA510(k) clearances K232915 and K250515 cover prescription adjunct monitoring of patterns associated with generalized tonic-clonic seizures, including patients aged6andolder, with caregiver alerts. It does not prevent seizures, diagnose every seizure type or guarantee detection. The physiological HealthMonitoringPlatform has separate clearance K242737. FDAK260374, decidedAugust14,2026 and announcedAugust19, covers Parkinson’s movement monitoring for individuals aged46to83: tremor, bradykinesia and dyskinesia quantification, medication reminders and sleep-associated activity. These are defined monitoring clearances, not unrestricted diagnostic or therapeutic approvals. Empatica acquired PKGHealth in2025, reported in its October1 own post, strengthening Parkinson’s algorithms and digital endpoints. The purchase consideration and precise acquired legal entity remain unpublished in the reviewed announcement. PKGHealth’s relationship to GlobalKineticsCorporation requires a separate legal-identity audit before investment records are attributed. A primary2014 FormD reports USD1,000,000 actually sold from a USD2,000,000 offering, with first saleApril17; exact final closing day is unpublished. The existing2016 USD5M/December1 financing and AllenTaylor personal investment are preserved. InvitaliaVenturesSGR’s own retrospective confirms completed Oct–Dec2016 SeriesA backing through ItaliaVentureI; the same legal manager was renamed CDPVentureCapitalSGR inJanuary2020. That primary statement does not independently establish the old personal-source amount or exact day. EndeavorCatalyst’s own retrospective separately confirms an Empatica investment in2017, with stage, day, ticket and priced-round allocation unpublished. OrigineSGR’s current portfolio dates historical InnogestSGR backing toQ4,2016 and reports a14.3% stake. Origine is the same legal manager renamed inOctober2025. These qualified backing relationships may overlap previously documented financing; their unknown amounts are not treated as additional cash raises, and ownership percentages are not investment tickets. The issuer announced its closed SeriesB onNovember22,2022, co-led by SanofiVentures and RA CapitalManagement with BlackOpalVentures participating; final round size was undisclosed. An earlier2022 SEC offering reported USD25,949,980 sold-to-date against USD33,949,997 offered, with first saleJuly21. That snapshot is qualified alongside the financing rather than duplicated as a separate August cash event or asserted as the final November total. Individual institutional tickets and subscribing funds remain unpublished. BARDA/DRIVe2019–2020 materials describe respiratory-infection research collaboration without establishing an exact actual award or disbursement in the reviewed sources. The2024 PROJECTREMOTE statement identifies Allucent as the BARDA award recipient and Empatica as a technology partner; the programme’s funding is not attributed to Empatica as equity or a company grant.

Develops and manufactures patented microstructured metal metamaterials for sound absorption, vibration control and lightweight construction. Its recyclable ABSORA sheet targets acoustic applications in industry, mobility and buildings while supporting automated production.

Provides document processing and workflow software that helps small businesses digitize and automate administrative work.